605 related articles for article (PubMed ID: 14613353)
1. Overview of pharmacologic therapy for the treatment of dyslipidemia.
Lipsy RJ
J Manag Care Pharm; 2003; 9(1 Suppl):9-12. PubMed ID: 14613353
[TBL] [Abstract][Full Text] [Related]
2. Role of colesevelam in combination lipid-lowering therapy.
Jones MR; Nwose OM
Am J Cardiovasc Drugs; 2013 Oct; 13(5):315-23. PubMed ID: 23913404
[TBL] [Abstract][Full Text] [Related]
3. Managing dyslipidemia in the high-risk patient.
Stein EA
Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
[TBL] [Abstract][Full Text] [Related]
4. The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review.
Davidson MH
Expert Opin Pharmacother; 2007 Oct; 8(15):2569-78. PubMed ID: 17931091
[TBL] [Abstract][Full Text] [Related]
5. LDL reduction: how low should we go and is it safe?
Robinson JG
Curr Cardiol Rep; 2008 Nov; 10(6):481-7. PubMed ID: 18950559
[TBL] [Abstract][Full Text] [Related]
6. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
Hou R; Goldberg AC
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
[TBL] [Abstract][Full Text] [Related]
7. Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia.
Florentin M; Liberopoulos EN; Mikhailidis DP; Elisaf MS
Curr Med Res Opin; 2008 Apr; 24(4):995-1009. PubMed ID: 18291066
[TBL] [Abstract][Full Text] [Related]
8. Management of dyslipidemia in the high-risk patient.
Stein EA
Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
[TBL] [Abstract][Full Text] [Related]
9. Utility of currently available modes of therapy in reaching lipid goals.
Spratt KA; Denke MA
J Am Osteopath Assoc; 2004 Sep; 104(9 Suppl 7):S14-6. PubMed ID: 15467019
[TBL] [Abstract][Full Text] [Related]
10. Colesevelam - a bile acid sequestrant for treating hypercholesterolemia and improving hyperglycemia.
Esan O; Viljoen A; Wierzbicki AS
Expert Opin Pharmacother; 2022 Aug; 23(12):1363-1370. PubMed ID: 35968655
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy for combined dyslipidemia.
Xydakis AM; Ballantyne CM
Am J Cardiol; 2002 Nov; 90(10B):21K-29K. PubMed ID: 12467937
[TBL] [Abstract][Full Text] [Related]
12. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance.
Rivers SM; Kane MP; Busch RS; Bakst G; Hamilton RA
Endocr Pract; 2007; 13(1):11-6. PubMed ID: 17360295
[TBL] [Abstract][Full Text] [Related]
13. Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol.
Corsini A; Windler E; Farnier M
Eur J Cardiovasc Prev Rehabil; 2009 Feb; 16(1):1-9. PubMed ID: 19237992
[TBL] [Abstract][Full Text] [Related]
14. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of daily statin use.
Reddy KJ; Singh M; Batsell RR; Bangit JR; Zaheer MS; John S; Varghese S; Molinella R
J Clin Hypertens (Greenwich); 2009 Dec; 11(12):766-8. PubMed ID: 20021539
[TBL] [Abstract][Full Text] [Related]
16. Colesevelam: a new and improved bile acid sequestrant?
Tziomalos K; Karagiannis A; Mikhailidis DP; Athyros VG
Curr Pharm Des; 2013; 19(17):3115-23. PubMed ID: 23317402
[TBL] [Abstract][Full Text] [Related]
17. Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent.
Davidson MH; Dicklin MR; Maki KC; Kleinpell RM
Expert Opin Investig Drugs; 2000 Nov; 9(11):2663-71. PubMed ID: 11060828
[TBL] [Abstract][Full Text] [Related]
18. Combination of a sterol absorption inhibitor and cardiovascular agents for the treatment of dyslipidemia.
Chrysohoou C; Singh S
Recent Pat Cardiovasc Drug Discov; 2006 Jan; 1(1):73-8. PubMed ID: 18221076
[TBL] [Abstract][Full Text] [Related]
19. Rationale for aggressive lipid lowering in high-risk patients.
Cohen JD
J Am Osteopath Assoc; 2011 Apr; 111(4 Suppl 3):eS7-12. PubMed ID: 21593473
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy.
Denke MA
J Manag Care Pharm; 2003; 9(1 Suppl):17-9. PubMed ID: 14613355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
